: The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a risk-adjusted safety analysis of event rates accounting for different time on treatment. While the rate of overall events was higher on pacritinib compared to BAT, the rate of fatal events was lower, and there was no excess in bleeding, cardiac events, secondary malignancy, or thrombosis on pacritinib, including in patients with severe thrombocytopenia.

Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis / Pemmaraju, Naveen; Harrison, Claire; Gupta, Vikas; Verstovsek, Srdan; Scott, Bart; Oh, Stephen T; Palandri, Francesca; Al-Ali, Haifa Kathrin; Sobas, Marta; McMullin, Mary Frances; Mesa, Ruben; Buckley, Sarah; Roman-Torres, Karisse; Vannucchi, Alessandro; Yacoub, Abdulraheem. - In: EJHAEM. - ISSN 2688-6146. - ELETTRONICO. - 3:(2022), pp. 1346-1351. [10.1002/jha2.591]

Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

Palandri, Francesca;Vannucchi, Alessandro;
2022

Abstract

: The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a risk-adjusted safety analysis of event rates accounting for different time on treatment. While the rate of overall events was higher on pacritinib compared to BAT, the rate of fatal events was lower, and there was no excess in bleeding, cardiac events, secondary malignancy, or thrombosis on pacritinib, including in patients with severe thrombocytopenia.
2022
3
1346
1351
Pemmaraju, Naveen; Harrison, Claire; Gupta, Vikas; Verstovsek, Srdan; Scott, Bart; Oh, Stephen T; Palandri, Francesca; Al-Ali, Haifa Kathrin; Sobas, M...espandi
File in questo prodotto:
File Dimensione Formato  
12.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 161.29 kB
Formato Adobe PDF
161.29 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1308726
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 5
social impact